Dubois' lupus erythematosus and related syndromes

著者

• Wallace, Daniel J. (Daniel Jeffrey)
• Hahn, Bevra H.
• Dubois, Edmund L.
• Askanase, Anca
• Crow, Mary K.
• Isenberg, David
• La Cava, Antonio
• McMahon, Maureen A.
• Tsao, Betty P.
• Venuturupalli, Swamy
• Weisman, Michael H.

書誌事項

Dubois' lupus erythematosus and related syndromes

edited by Daniel J. Wallace, Bevra Hannahs Hahn ; associate editors, Anca Askanase ... [et al.]

Elsevier, c2025

10th ed

タイトル別名

Lupus erythematosus and related syndromes

注記

other associate editors: Mary K. Crow, David A. Isenberg, Antonio La Cava, Maureen A. McMahon, Betty P. Tsao, Swamy Venuturupalli, Michael H. Weisman

Includes bibliographical references and index

内容説明・目次

内容説明

For more than 50 years, Dubois’ Lupus Erythematosus and Related Syndromes has been recognized internationally as the go-to clinical reference on lupus and other connective tissue diseases. From basic scientific principles to practical points of clinical management, the 10th edition provides extensive, authoritative coverage of systemic lupus erythematosus (SLE) and its related diseases in a logical, clearly written, user-friendly manner. It’s an ideal resource for rheumatologists and internal medicine practitioners who need a comprehensive clinical reference on all aspects of SLE, connective tissue diseases, and the antiphospholipid syndromes. Provides complete clinical coverage of every aspect of cutaneous and systemic lupus erythematosus, including definitions, pathogenesis, autoantibodies, clinical and laboratory features, management, prognosis, and patient education. Includes significant new content throughout: a new chapter on the endocrine system and hormones; newly distinct chapters on the heart and lung; new content on social disparities in lupus, clinical presentation of nephritis, and pulmonary hypertension; a new concluding chapter on future directions in the field; new basic science coverage of the microbiome, autoinflammatory, and monogenic lupus; and new coverage of diversity, inclusion, gender, compliance, and adherence. Offers a fresh perspective from two new associate editors and many new authors with representation from 30 countries. Contains an up-to-date overview of significant advances in cellular, molecular, and genetic technologies, including genetic advancements in identifying at-risk patients. Discusses the clinical management of related disorders such as Sjogren’s syndrome, scleroderma, polymyositis, and antiphospholipid syndrome (APS). Presents the knowledge and expertise of international contributors to provide new global perspectives on manifestations, diagnosis, and treatment. Features a vibrant, full-color format, with graphs, algorithms, differential diagnosis comparisons, new and improved figures, and schematic diagrams throughout. An eBook version is included with purchase. The eBook allows you to access all of the text, figures, and references, with the ability to search, customize your content, make notes and highlights, and have content read aloud. Additional digital ancillary content may publish up to 6 weeks following the publication date.

目次

SECTION 1 What Is Lupus? 1 History of Lupus 2 Definition and Classification of Lupus and Lupus-Related Disorders 3 The Epidemiology of Lupus SECTION 2 Pathogenesis 4 Overview of Lupus Pathogenesis 5 Genetics of SLE 6 Single Gene Defects and Autoinflammation: Relation to Lupus 7 Epigenetics of Lupus 8 The Role of the Environment and Microbiome in Lupus 9 The Innate Immune System in SLE 10 B Cells and Generation of Antibodies 11 T cells 12 Immunoregulatory Cells and Networks in Lupus 13 Cytokines in Lupus 14 Metabolic Control of Immunopathogenesis in Systemic Lupus Erythematosus 15 Animal Models of Systemic Lupus Erythematosus (SLE) SECTION 3 Mechanisms of Tissue Injury 16 Abnormalities in Clearance of Immune Complexes and Dying Cells in Lupus 17 Complement and Systemic Lupus Erythematosus 18 Apoptosis and Inflammatory Forms of Cell Death 19 Tissue Damage in Lupus: Free Radicals and Fibrosis 20 Lupus Nephritis 21 Pathogenesis of Accelerated Atherosclerosis and Vascular Injury in Systemic Lupus Erythematosus 22 Pathogenesis of Cutaneous Lupus 23 Pathogenesis of Neuropsychiatric Lupus 24 Pathogenesis of Sjögren Syndrome SECTION 4 Autoantibodies 25 Antinuclear Antibodies, Antibodies to DNA, Histones, and Nucleosomes 26 Antibodies Against Extractable Nuclear Antigens(RNP, Sm, SS-A/Ro, and SS-B/La) 27 Other Autoantibodies: Antibodies to C1q, Lipoprotein, and Endothelial Cells 28 Pathogenesis of Antiphospholipid Antibody Syndrome 29 Drug-Induced Lupus SECTION 5 Clinical Aspects of Lupus Erythematosus 30 Overview and Clinical Presentation 31 Skin Disease in Cutaneous Lupus Erythematosus 32 The Musculoskeletal System and Bone Metabolism 33 Lupus and the Cardiovascular System 34 Pulmonary Manifestations of Systemic Lupus Erythematosus 35 Lupus and the Nervous System: Clinical Presentation, Diagnosis, and Treatment 36 Gastrointestinal and Hepatic Manifestations 37 The Gut Microbiome and Lupus Pathogenesis 38 Hematologic and Lymphoid Abnormalities in SLE 39 Neonatal Lupus: Pathogenesis and Clinical Approaches 40 Pregnancy and Reproductive Health Issues in Systemic Lupus Erythematosus 41 Systemic Lupus Erythematosus in Childhood and Adolescence 42 Clinical Aspects of Antiphospholipid Syndrome 43 Lupus and Infections 44 Ocular, Aural, and Oral Manifestations of Lupus 45 Clinical Aspects of Sjögren’s Disease 46 Clinical Presentations of Lupus in the Kidney and Urogenital System 47 The Endocrine System and Hormones in Lupus SECTION 6 Assessment of Lupus 48 Clinical Application of Serologic Tests, Serum Protein Abnormalities, and Other Laboratory Tests in Systemic Lupus Erythematosus 49 Differential Diagnosis and Disease Associations 50 Incomplete Lupus, Undifferentiated Connective Tissue Disease, and Mixed Connective Tissue Disease 51 Clinical Markers, Metrics, Indices, and Clinical Trials SECTION 7 Management of Lupus 52 Principles of Therapy, Local Measures, and NSAIDs 53 Antimalarial Medications 54 Systemic Glucocorticoid Therapy for SLE 55 Immunosuppressive Drug Therapy 56 Complementary and Integrative Health Approaches 57 Specialized and Niche Therapies 58 Adjunctive and Preventive Measures 59 Management of Cutaneous Lupus Erythematosus 60 Targeted Therapies in SLE 61 Management of Lupus Nephritis 62 Management of Sjögren Disease Syndrome SECTION 8 Outcomes 63 Socioeconomics, Disparities, and Disability 64 Prognosis and Mortality of Systemic Lupus Erythematosus 65 Future Directions: Therapeutics 66 Expanding the Opportunities to Effectively Treat Patients: Clinical Considerations Index

「Nielsen BookData」 より

詳細情報

• NII書誌ID(NCID): BD07292362
• ISBN:
  • 9780323932325
• 出版国コード: us
• タイトル言語コード: eng
• 本文言語コード: eng
• 出版地: Philadelphia, PA
• ページ数/冊数: xvi, 910 p.
• 大きさ: 28 cm